ASCENDIS PHARMA BONE DISEASES A/S: Financial statements 2019
CVR: 32323596
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
ASCENDIS PHARMA BONE DISEASES A/S (CVR 32323596) has filed annual accounts for 2019. In 2019, the company reported a gross profit of EUR -27,475,665 and a net result of EUR -28,817,684 compared with EUR -19,845,085 the year before. Equity in the 2019 report amounted to EUR -73,847,129.
- Gross Profit
- EUR -27,475,665
- Profit/Loss
- EUR -28,817,684
- Equity
- EUR -73,847,129
- Total Assets
- EUR 14,855,574
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | - | -27.5 mio. EUR | -28.8 mio. EUR | -73.8 mio. EUR | 0 |
| 2018 | - | -18.9 mio. EUR | -19.8 mio. EUR | -45 mio. EUR | 0 |
| 2017 | - | -16.2 mio. EUR | -16.6 mio. EUR | -25.2 mio. EUR | 0 |
| 2016 | - | -6.4 mio. EUR | -6.6 mio. EUR | -8.6 mio. EUR | - |
| 2015 | - | -137 t. EUR | -279 t. EUR | -1.9 mio. EUR | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
ASCENDIS PHARMA BONE DISEASES A/S has published its annual report for 2018. Gross profit came to DKK -18,881,606, and the net result was DKK -19,845,085.
About ASCENDIS PHARMA BONE DISEASES A/S
ASCENDIS PHARMA BONE DISEASES A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named ASCENDIS PHARMA OSTEOARTHRITIS DIVISION A/S and ASCENDIS PHARMA RHEUMATOLOGY DIVISION A/S. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of EUR 229,581,000 and a net result of EUR 134,982,000 compared with EUR -139,088 the year before. Equity in the 2025 report amounted to EUR -372,183,000.